{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.5"}]}],"title":"Subject 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.09"}]}],"title":"Subject 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7"}]}],"title":"Subject 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50"}]}],"title":"Subject 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6"}]}],"title":"Subject 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.5"}]}],"title":"Subject 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"All patients received 0.7 mg/m2 of bortezomib on days 1, 4, 8 and 11 of a 21 day cycle, for maximum of three cycles for an average of 18 months. Intact Parathyroid hormone was measured in patients with relapsed/refractory myeloma for osteoblast activation. Other bone markers were examined using similar methods.","groups":[{"description":"All participants enrolled.\n\nBortezomib (Velcade): Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.\n\nPatients will undergo three 21-day cycles.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1","title":"Maximum Percent Change From Baseline in Intact Parathyroid Hormone Levels on Day 1","type":"PRIMARY","unitOfMeasure":"% change"}